文献速递炎症性肠病

戈利木单抗治疗克罗恩病的疗效与安全性:法国全国回顾性研究

Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study.
PubMed 文献 · Aliment Pharmacol Ther · 2017-10-13

本研究在法国12家三级中心回顾性分析了115例接受戈利木单抗治疗的克罗恩病患者,中位治疗持续时间为9.8个月,55.8%的患者在平均3.8个月时出现临床应答,6%、12%、24个月无升级维持治疗概率分别为54.6%、34.9%、19.3%,6%因不耐受停药。

要点

  • 戈利木单抗治疗克罗恩病中位持续9.8个月,末次随访时48.7%仍在治疗。
  • 55.8%患者平均3.8个月出现临床应答,6%因不耐受停药。
  • 因不耐受停用第一种抗TNF药及联合免疫抑制超过6个月为疗效预测因素。

核心结论

  • 在英夫利西单抗或阿达木单抗治疗克罗恩病失败后,戈利木单抗是安全的,且似乎对半数患者有益。

研究设计与样本

  • 在法国12家三级中心识别接受戈利木单抗治疗的克罗恩病患者并进行回顾性分析,共纳入115例患者。

主要发现

  • 戈利木单抗治疗持续时间为9.8个月(0.55-44),末次随访时48.7%的患者仍在治疗。
  • 55.8%的患者在平均3.8个月后出现临床应答,临床应答定义为Harvey-Bradshaw指数下降超过3分或基于整体医师评估。
  • 6、12、24个月无升级维持治疗的概率分别为54.6%、34.9%、19.3%。
  • 多因素分析中,因不耐受停用第一种抗TNF药物(OR=2.16;95%CI [1.25-3.86];P=.005)和联合免疫抑制超过6个月(OR=3.98;95%CI [2.3-7.1];P<.0001)为疗效预测因素。
  • 6%的患者因不耐受停止治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-tumour necrosis factor (TNF) agents have improved the care of Crohn's disease (CD). After the first anti-TNF discontinuation, it is possible to switch to another anti-TNF. Three anti-TNF agents are available for ulcerative colitis (infliximab, adalimumab and golimumab), but only the first 2 have been approved for CD because golimumab has not been studied for this indication. AIM: To report the efficacy and safety of golimumab in CD. METHODS: Crohn's disease patients who received golimumab were identified in 12 French tertiary centres and were retrospectively analysed. The primary endpoint was the duration of golimumab treatment before escalation or discontinuation. The clinical response was defined as a decrease of more than 3 points in the Harvey-Bradshaw index or by global physician assessment. RESULTS: One hundred and fifteen patients were included. The golimumab treatment duration was 9.8 months (0.55-44), and 48.7% of the patients were still under treatment at the end of follow-up. Clinical response was observed in 55.8% of the patients after a mean duration of 3.8 months. The probability of remaining under treatment without escalation at 6, 12 and 24 months was 54.6%, 34.9% and 19.3% respectively. In multivariate analysis, discontinuation of the first anti-TNF agent due to intolerance (odds ratio, OR = 2.16; 95% CI, confidence interval [1.25-3.86]; P = .005) and co-immunosuppression for more than 6 months (OR = 3.98; 95% CI [2.3-7.1]; P < .0001) were predictive factors of efficacy. Six per cent of the patients discontinued treatment due to intolerance. CONCLUSION: After failure of infliximab or adalimumab for Crohn's disease, golimumab was safe and seemed beneficial in half of the patients.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Martineau C, Flourié B, Wils P, et al. Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study. Aliment Pharmacol Ther. 2017. PMID: 29027693. doi:10.1111/apt.14371

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。